AbbVie Inc. · Q4 2022
ReportedFeb 9, 2023
Period endedDec 31, 2022
Rule of 40+49
The quarter in short
Revenue $15.12B, up 1.6% year over year and 2.1% on the quarter. EPS $1.40, down 38.1% year over year and 36.7% on the quarter. Free cash flow $7.21B, up 47.6% year over year and down 2.8% on the quarter. Rule of 40 score +49.
Reported this quarter
Revenue
$15.12B
QoQ +2.1%
YoY +1.6%
EPS
$1.40
QoQ −36.7%
YoY −38.1%
Free Cash Flow
$7.21B
QoQ −2.8%
YoY +47.6%
Gross Margin
72.4%
QoQ +6.3 pp
YoY +1.4 pp
FCF Margin
47.7%
QoQ −2.4 pp
YoY +14.9 pp
P/E Ratio
21.7
QoQ +37.9%
YoY +21.0%
Each tile opens the full quarterly series. Download the numbers as CSV or JSON.
Sources & downloads
Company
Published by the company on the day of the release.
HTML
Earnings press release
Investor relations announcement
SEC filings
Filed with the SEC under CIK 1551152.
HTML
8-K results announcement
Filed Feb 9, 2023
HTM
Press release (EX-99.1)
Exhibit 99.1 to the 8-K
460 KB
HTML
Filing index
Every document in the 8-K submission
TXT
Complete submission
Raw archival text of the whole filing
HTML
10-K annual report
Period ended Dec 31, 2022, filed Feb 17, 2023
ZIP
XBRL data bundle
Structured financial statements from the 10-K
JSON
Company facts (XBRL)
Every figure ABBV has reported to the SEC
R40 data
The numbers shown on this page, as we hold them.
CSV
This quarter (CSV)
Reported metrics for Q4 2022, spreadsheet-ready
JSON
This quarter (JSON)
Metrics, dates and matched filings